Commentary on “Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75.” Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ; Hoosier Oncology Group, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN: J Clin Oncol 2011;29:1525–30

✍ Scribed by H. Barton Grossman

• Book ID: 116956854
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 85 KB
• Volume: 30
• Category: Article
• ISSN: 1078-1439
• DOI: 10.1016/j.urolonc.2011.11.019